GHSI (guardionhealth.com) Market Value to Book Value Ratio

Official company branding of Guardion Health Sciences, Inc. (GHSI)

Guardion Health Science relies on patient trust in its evidence-based vision nutraceuticals. Brand distribution synergy is driven by partnerships with clinics to promote Lumega-Z, while the environmental footprint is minimized through outsourced manufacturing. The company's relative capitalization metric confirms the market consensus, with the latest value recorded as 0.30.

GHSI Guardion Health: Market Value to Book Value in the range 07/04/2022 - 10/19/2024

Financial and market metric breakdowns for Guardion Health Sciences, Inc. (GHSI)

- price and consensus price forecast:
Stock Price Guardion Health Science|GHSI - Analyst Median Target
- market capitalization data:
Market Value Guardion Health|GHSI - Full Business Value
- book capitalization data:
Book Value per Share Guardion Health Sciences|GHSI - Accounting Value of Company|Market Capitalization to Book Value Ratio guardionhealth.com|GHSI - Company Total Assets
- debt and liquidity data:
Debt to Equity Guardion Health Science|GHSI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Guardion Health Sciences Inc.|GHSI - Company Total Debt|Debts to Book Capitalization Guardion Health
Initial company analysis:Guardion Health Science - GHSI
Original product of Guardion Health Sciences Inc.

To filter risks for Guardion Health Science (GHSI), it is necessary to assess the degree of asset overvaluation. This indicator is calculated as the ratio of market value to net assets, measuring the gap between exchange quotes and book value. Analyzing the change in the market-to-book value ratio reveals speculative deviations from the fundamental base. For Guardion Health Science, such a premium reflects market confidence in the capital of ophthalmologist-scientists and the value of their evidence-based research.

Main competitors

Alcon Inc. - Market Capitalization to Book Value Ratio|BLCO (bausch.com) - Market Capitalization to Book Value|Market Value to Book Value Ratio Glaukos GKOS|Market Capitalization to Net Assets Apellis Pharmaceuticals, Inc.|Belite Bio, Inc. (BLTE) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ocular Pharma (OCUL)|Market Capitalization to Book Value Ratio HROW (Harrow, Inc.)|viridiantherapeutics.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio LENZ Therapeutics (LENZ)|OCS: Market Value to Book Value|EYPT (EyePoint Pharma) - Market Value to Book Value Ratio|Kodiak Corp (KOD) - Market Cap to Net Assets Ratio|ALDX (Aldeyra Therapeutics Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Kala Pharmaceuticals (KALA)|Opus Genetics Inc (IRD) - Market Cap to Net Assets Ratio|Market Value to Book Value okyopharma.com (OKYO)|ADVM: Market Capitalization to Book Value Ratio|OTLK - Market-to-Book Ratio|CLSD (Clearside Biomedical) - Market Cap to Net Assets Ratio|NBY - Market-to-Book Ratio|Market Capitalization to Book Value Ratio KPRX|ALIM (Alimera Sciences, Inc.) - Market-to-Book Ratio|EYEN: Market Value to Book Value Ratio|Market Capitalization to Book Value Ocuphire Corporation|OPT: Market Capitalization to Book Value Ratio